-
Deracoxib Workflows for COX-2 and Cancer Assays
2026-09-07
Build more informative inflammation and canine cancer experiments with Deracoxib, a selective COX-2 inhibitor suited to dose-response, apoptosis, and cell-cycle workflows. This guide connects practical solvent handling and assay optimization with evidence from canine mammary tumor research, while distinguishing exploratory in vitro concentrations from clinically relevant exposure.
-
L-NAME Hydrochloride: From NO Biology to Translation
2026-09-07
A translational framework for using L-NAME Hydrochloride and NG-nitro-L-arginine methyl ester to connect NOS inhibition with vascular physiology, inflammatory signaling, and more rigorous disease-model interpretation.
-
ATP Solution (100 mM): Reliable mRNA Assays
2026-09-05
Learn how ATP Solution (100 mM), SKU K1043, can standardize ATP-dependent transcription, kinase, ligation, and phosphorylation workflows that support cell viability and p21 mRNA–LNP research. The article translates product specifications into practical guidance for handling, controls, interpretation, and vendor selection.
-
2-Hydroxypropyl-β-cyclodextrin Protocol Guide
2026-09-04
2-Hydroxypropyl-β-cyclodextrin is a water-compatible cyclic oligosaccharide used to screen the apparent aqueous solubility of poorly soluble hydrophobic compounds, especially molecules containing aromatic or phenyl groups. It is appropriate for excipient and biochemical solubility workflows, but complexation, stability, bioavailability, and biological performance require assay-specific validation.
-
LAG-3–TCR Proximity in T-Cell Suppression
2026-09-04
A 2025 Cell study shows that LAG-3-mediated inhibition depends not simply on MHC class II binding, but on spatial proximity between LAG-3 and the T cell receptor (TCR). Its mechanistic and therapeutic experiments connect this proximity to CD3ε/Lck disruption and demonstrate that an Fc-attenuated LAG-3/TCR bispecific antibody can suppress pathogenic T-cell activity in autoimmune models.
-
Dextromethorphan Hydrobromide for Neuroprotection
2026-09-03
Build reproducible excitotoxicity and ion-channel assays with Dextromethorphan hydrobromide, an NMDA receptor antagonist suited to mechanistic neuroprotection research. This guide combines formulation, dose-response design, electrophysiology, cerebral ischemia model planning, and troubleshooting while clearly separating established product specifications from workflow recommendations.
-
Acifran: Practical HCAR Signaling Workflows
2026-09-03
Use Acifran to connect HCAR2/HCAR3 receptor pharmacology with cAMP and lipid metabolism experiments. This workflow emphasizes paired-receptor comparisons, structure-informed assay design, reproducible dosing, and troubleshooting rather than relying on a single downstream lipid endpoint.
-
Protease Inhibitor Cocktail for TCR Signaling Assays
2026-09-02
Learn how a Protease Inhibitor Cocktail EDTA-Free can preserve native TCR–LAG-3 complexes, phosphorylation states, and protein interactions during immunology workflows. This guide translates a recent mechanistic study into practical sample-preparation decisions for Western blotting, co-immunoprecipitation, and kinase assays.
-
Dual Luciferase Reporter Gene System for BMSC Studies
2026-09-02
Use the Dual Luciferase Reporter Gene System to connect MRF, FSHR, and cAMP-PKA-CREB regulation with quantitative promoter and pathway readouts in BMSCs. Its paired firefly and Renilla signals support normalization, while direct reagent addition streamlines mammalian cell culture luciferase assays and screening workflows.
-
Oleic Acid Workflows for Lipid Metabolism
2026-09-01
Use Oleic Acid (C18:1(9Z)) to build controlled lipid-loading, inflammation, and signaling assays rather than relying on undefined lipid mixtures. This guide translates hepatic ischemia-reperfusion research into practical dosing, controls, readouts, and troubleshooting strategies.
-
Carbenoxolone disodium: Practical Lab Guide
2026-09-01
Carbenoxolone disodium is an 11β-hydroxysteroid dehydrogenase inhibitor for controlled studies of glucocorticoid access, corticosterone metabolism, and gap junction communication. It is most appropriate for cell, tissue, and biochemical workflows with matched vehicle and orthogonal controls, not for selective in vivo efficacy claims or clinical interpretation.
-
NIID iPSC Model with NOTCH2NLC GGC Expansion
2026-08-31
The reference study establishes HZSMHCi002-A, a patient-derived induced pluripotent stem cell line carrying a pathogenic NOTCH2NLC GGC repeat expansion associated with neuronal intranuclear inclusion disease. Its documented pluripotency, genomic stability, donor matching, and three-germ-layer differentiation make it a useful starting point for mechanistic NIID research, although disease-specific phenotypes still require validation in differentiated cells.
-
Tamsulosin: From POUR Evidence to Assays
2026-08-31
Tamsulosin can connect clinical urinary-flow outcomes with mechanistic smooth muscle and GPCR studies. This article shows how the POUR meta-analysis can guide model selection, endpoints, controls, and compound handling without overextending clinical evidence.
-
CUX2 Neuron Loss Under Neuroinflammatory DNA Damage
2026-08-30
This study identifies accumulated DNA damage and insufficient double-strand-break repair as a mechanism underlying the selective loss of CUX2-positive layer 2/3 excitatory neurons in multiple sclerosis and mouse neuroinflammation models. Its combination of human lesion analysis, experimental inflammation, neuronal genetic perturbation, and interferon-γ modeling provides a framework for studying cell-type-specific neuronal vulnerability.
-
LncRNA MRF, FSHR, and BMSC Osteogenesis
2026-08-29
Ning et al. identify lncRNA MRF as a negative regulator of BMSC osteogenic differentiation and bone defect repair. Their data connect MRF with FSHR-dependent cAMP–PKA–CREB signaling, providing a mechanistic framework for studying lncRNA control of skeletal regeneration.